Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.

[1]  N. Seki,et al.  Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow. , 2010, International immunology.

[2]  K. Chiba.  Sphingosine 1-phosphate receptor type 1 as a novel target for the therapy of autoimmune diseases , 2010 .

[3]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[4]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[5]  X. Montalban,et al.  Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results , 2010, Multiple sclerosis.

[6]  V. Brinkmann.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system , 2009, British journal of pharmacology.

[7]  B. Segal,et al.  IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition , 2008, The Journal of experimental medicine.

[8]  J. Goverman,et al.  Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells , 2008, Nature Medicine.

[9]  J. Cyster,et al.  S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. , 2008, Immunity.

[10]  E. Persohn,et al.  Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis , 2007, Journal of Pharmacology and Experimental Therapeutics.

[11]  C. A. Foster,et al.  FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis , 2007, Brain Research Bulletin.

[12]  H. Matsuyuki,et al.  Migration of CD4 T Cells and Dendritic Cells toward Sphingosine 1-Phosphate (S1P) Is Mediated by Different Receptor Subtypes: S1P Regulates the Functions of Murine Mature Dendritic Cells via S1P Receptor Type 3 , 2007, The Journal of Immunology.

[13]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[14]  S. Nakae,et al.  IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[15]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[16]  H. Matsuyuki,et al.  Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. , 2006, Cellular & molecular immunology.

[17]  M. Koyama,et al.  FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. , 2005, Cellular & molecular immunology.

[18]  K. Chiba.  FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. , 2005, Pharmacology & therapeutics.

[19]  K. Adachi,et al.  Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. , 2005, Bioorganic & medicinal chemistry.

[20]  R. Proia,et al.  Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit , 2005, The Journal of experimental medicine.

[21]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[22]  J. Chun,et al.  Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice , 2004, Journal of Neuroimmunology.

[23]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[24]  H. Amemiya,et al.  Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment , 2003, Journal of Pharmacology and Experimental Therapeutics.

[25]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[26]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[27]  T. Fujita,et al.  Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720 , 1995 .

[28]  V. Kuchroo,et al.  Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. , 1993, Journal of immunology.

[29]  L. Steinman.  Mixed results with modulation of TH-17 cells in human autoimmune diseases , 2010, Nature Immunology.

[30]  J. Cyster,et al.  Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. , 2005, Annual review of immunology.

[31]  H. McFarland,et al.  Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. , 1995, Critical reviews in clinical laboratory sciences.

[32]  D. McFarlin,et al.  Immunological aspects of demyelinating diseases. , 1992, Annual review of immunology.